Tzield (Teplizumab) for Type 1 Diabetes

Overview
Tzield is a medication approved by the U.S. Food and Drug Administration (FDA) for delaying the onset of stage 3 type 1 diabetes in individuals aged 8 years and older who have stage 2 type 1 diabetes. It is also known by its drug name, teplizumab.

As a cluster of differentiation 3 (CD3)-directed monoclonal antibodies, teplizumab is believed to work by modulating the immune system to delay the progression to stage 3 diabetes, where significant insulin-production impairment occurs​​​​​​.

How do I take it?
Tzield is given through intravenous injection by a health care professional. The specifics of the treatment administration, including preparation and scheduling, should be discussed with your health care provider​​.

Side Effects
Common side effects of Tzield are rash, leukopenia (a reduction in white blood cells), and headache. Serious side effects include cytokine release syndrome (CRS), which causes fever, nausea, fatigue, headache, muscle and joint pain, and elevated liver enzymes. A decrease in lymphocytes, a type of white blood cell, is also a serious side effect and can compromise the body’s infection-fighting capabilities.

Additional serious risks involve severe infections and hypersensitivity reactions.

For more details about this treatment, visit:

Tzield — Teplizumab-Mzwv Injection — DailyMed
https://dailymed.nlm.nih.gov/dailymed/drugInfo....

Tzield — Sanofi
https://www.tzield.com